Umeclidinium Bromide Vilanterol (Anoro Ellipta) (COPD) (Wave 1) | LaunchTrends | US | 2014

This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. The syndicated primary research reports will examine physician perceptions at one month, six months and one year following the commercial availability of Anoro Ellipta. The reports will also investigate where Anoro Ellipta will fit into the treatment algorithm, likely patient candidates, perceived advantages and disadvantages of the product and GlaxoSmithKline’s promotional efforts.

Login to access report